Last reviewed · How we verify
LBH589, Paclitaxel, Carboplatin, Bevacizumab
LBH589, Paclitaxel, Carboplatin, Bevacizumab is a Small molecule drug developed by SCRI Development Innovations, LLC. It is currently in Phase 1 development.
At a glance
| Generic name | LBH589, Paclitaxel, Carboplatin, Bevacizumab |
|---|---|
| Sponsor | SCRI Development Innovations, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (PHASE1)
- LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LBH589, Paclitaxel, Carboplatin, Bevacizumab CI brief — competitive landscape report
- LBH589, Paclitaxel, Carboplatin, Bevacizumab updates RSS · CI watch RSS
- SCRI Development Innovations, LLC portfolio CI
Frequently asked questions about LBH589, Paclitaxel, Carboplatin, Bevacizumab
What is LBH589, Paclitaxel, Carboplatin, Bevacizumab?
LBH589, Paclitaxel, Carboplatin, Bevacizumab is a Small molecule drug developed by SCRI Development Innovations, LLC.
Who makes LBH589, Paclitaxel, Carboplatin, Bevacizumab?
LBH589, Paclitaxel, Carboplatin, Bevacizumab is developed by SCRI Development Innovations, LLC (see full SCRI Development Innovations, LLC pipeline at /company/scri-development-innovations-llc).
What development phase is LBH589, Paclitaxel, Carboplatin, Bevacizumab in?
LBH589, Paclitaxel, Carboplatin, Bevacizumab is in Phase 1.